UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported) — December 12, 2006

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

 

1-8036

 

23-1210010

(State or other jurisdiction
of incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

101 Gordon Drive, PO Box 645,

 

 

 

 

Lionville, PA

 

 

 

19341-0645

(Address of principal executive offices)

 

 

 

(Zip Code)

 

610-594-3319

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 



Item 5.02                            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

 

e)                          On December 12, 2006 the Board of Directors of West Pharmaceutical Services, Inc. increased the annual salary of the Company’s Chief Executive Officer and Chairman of the Board Dr. Donald E. Morel, Jr. to $775,000 from $675,000.  Dr. Morel’s salary increase was effective on December 12, 2006.

The Board of Directors also increased Dr. Morel’s annual bonus opportunity to 100% of his base salary. The increase in bonus opportunity is effective for the 2007 fiscal year.

2



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

WEST PHARMACEUTICAL SERVICES, INC.

 

 

 

/s/ John R. Gailey III

 

John R. Gailey III

 

Vice President, General Counsel and Secretary

 

December 18, 2006

3